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Adoptive therapy of cancer with genetically redirected
T cells showed spectacular efficacy in recent trials. A body
of pre-clinical and clinical data indicate that young effector
and central memory T cells perform superior in a primary
anti-tumor response; repetitive antigen engagement, how-
ever, drives T cell maturation to terminally differentiated
cells associated with the loss of CCR7 which enables
T cells to persist in peripheral tissues. Chimeric antigen
receptor (CAR) engineered CCR7- T cells more efficiently
accumulated at the tumor site, secreted more IFN-g,
expressed higher amounts of cytotoxic molecules and
showed superior tumor cell lysis compared to the younger
CCR7+ cells. CCR7- T cells, however, were more prone to
spontaneous and activation induced cell death which
could be counteracted by simultaneous CD28 and OX40
(CD134) costimulation. Consequently, the combined
CD28-z-OX40 signaling CAR rescued CCR7- T cells from
apoptosis which then produced more efficient anti-tumor
efficacy than CCR7+ T cells redirected by the same CAR.
In contrast, cytokine induced killer (CIK) cells, predomi-
nantly consisting of terminally differentiated CD8+CD56+
cells, accelerated terminal maturation of CD56+ CIK cells
producing high frequencies in activation induced cell
death (AICD) and reduced anti-tumor efficiency when sti-
mulated by the CD28-z-OX40 CAR compared to the
CD28-z CAR. Translated into therapeutic strategies, T cell
therapy will benefit from combined CD28-z-OX40 stimu-
lation in the long-term by rescuing continuously generated
CCR7- T cells for an anti-tumor attack. CAR redirected
CIK cells benefit from CD28 co-stimulation; “super-costi-
mulation” by the CD28-z-OX40 CAR, however, performed
less in anti-tumor efficacy due to increased AICD.
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